Thermo Fisher Scientific Inc (TMO) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown solid financial performance and positive analyst sentiment, the technical indicators suggest a bearish trend, and insider selling is a significant negative catalyst. Additionally, options data indicates bearish sentiment, and there are no strong trading signals from Intellectia Proprietary Trading Signals to support an immediate buy decision.
The technical indicators for TMO show a bearish trend. The MACD histogram is negative (-1.33), RSI is neutral (33.606), and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with support at 463.687 and resistance at 485.092.

Strong financial performance in Q4 2025, with revenue up 7.20% YoY, net income up 7.32% YoY, and EPS up 8.79% YoY.
Positive analyst sentiment, with multiple firms raising price targets and maintaining Buy or Outperform ratings.
Recovery in end markets and sector rotation setting up for potential growth in 2026.
Insider selling has increased significantly (up 3567.45% over the last month), signaling potential lack of confidence from insiders.
Options data reflects bearish sentiment, with high put option activity.
Technical indicators suggest a bearish trend, with the stock trading below key moving averages and pivot levels.
Thermo Fisher reported strong Q4 2025 financials, with revenue increasing to $12.215 billion (up 7.20% YoY), net income rising to $1.964 billion (up 7.32% YoY), and EPS improving to $5.2 (up 8.79% YoY). However, gross margin dropped to 41.02%, down 3.07% YoY.
Analysts are broadly positive on TMO, with multiple firms raising price targets recently. Stifel has the highest target at $700, while Citi, Barclays, and TD Cowen also raised targets to $685, $650, and $696, respectively. Most analysts maintain Buy or Outperform ratings, citing recovery in end markets and strong growth potential for 2026.